This paper is only available as a PDF. To read, Please Download here.
In contrast to all other oestrogens examined thus far oestriol hemisuccinate (12 mg/day) did not prevent bone loss in 28 postmenopausal women. The average bone loss, however, was somewhat less than expected from placebo studies, while the bone loss achieved by a group taking 4–6 mg/day was equal to that achieved by previous placebo groups. To be an effective agent for prevention of post-menopausal osteoporosis oestriol would have to be prescribed in daily doses considerably in excess of 12 mg.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Maturitas
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Oestrogen replacement therapy for the prevention of osteoporosis after oophorectomy.Br. Med. J. 1973; ii: 515-518
- Long-term prevention of postmenopausal osteoporosis by oestrogen.in: Evidence for an increased bone mass after delayed onset of oestrogen treatment. 3rd ed. Lancet. i. 1976: 1038-1041
- Comparative effects of oestrogen and a progestogen on bone loss in postmenopausal women.Clin. Sci. Mol. Med. 1978; 54: 193-195
- Effect of long-term oestrogen therapy on bone remodelling in women with a natural menopause: cross-sectional and longitudinal study.in: van Keep P. Consensus on menopause research. MTP Press, Lancaster1976: 124-131
- Effect of oestrogens and calcium carbonate on bone loss in postmenopausal women.Annals Intern. Med. 1977; 87: 649-655
- Prospective trial of oestrogen and calcium in postmenopausal women.Br. Med. J. 1977; ii: 789-792
- Association of exogenous oestrogen and endometrial carcinoma.New Engl. J. Med. 1975; 293: 1164-1167
- Increased rise of endometrial carcinoma among users of conjugated oestrogens.New Engl. J. Med. 1975; 293: 1167-1170
- Bone response to termination of oestrogen treatment.Lancet. 1978; i: 1325-1327
- Estriol in the management of the menopause.J. Am. Med. Assoc. 1978; 239: 1638-1641
- Determination of calcium in urine and serum by atomic absorption spectrophotometry.Clin. Chem. 1967; 13: 101-114
- Procedures for plasma microanalysis in medical biochemistry.3rd ed. Churchill, London1956
- The accuracy and reproducibility of bone mineral measurements “in vivo” (b) Methods using sealed isotope sources.Clin. Radiol. 1972; 23: 47-51
- Effects of oestrogen and progestogen therapy on calcium metabolism in postmenopausal women.Front. Horm. Res. 1975; 3: 150-176
- Endometrial response to different estrogens.in: Estrogen therapy: the benefits and risks. Second ed. Frontiers of hormone research. Vol. 5. Karger, Basel1978: 126-144
- The effect of long-term Lynestrenol treatment on bone mass in cyclic women.Contraception. 1977; 15: 717-723
- Estriol: the forgotten estrogen.J. Am. Med. Assoc. 1978; 239: 29
- Vascular complications of long-term oestrogen therapy.Front. Horm. Res. 1978; 5: 174-191
Accepted: February 7, 1979
Received: December 11, 1978
© 1979 Published by Elsevier Inc.